

Claim Version with markings showing changes made

1. (Presently amended) A method of administering a secretorially reducing amount of botulinum toxin to a patient having excess levels of ~~(controlling the)~~ secretions from holocrine glands ~~(selected from the group consisting of holocrine glands, and the holocrine-like components of cerumen and mammary glands in)~~ whereby the excess ~~[a patient whose]~~ level of glandular secretion ~~[is greater than is desirable by administering to]~~ in said patient ~~(a secretorily controlling amount of botulinum toxin)~~ is reduced.

2. (Originally filed) The method of claim 1 wherein the holocrine glands are selected from the group consisting of sebaceous glands, pilosebaceous glands, meibomium glands, and glands of Zeiss and Moll.

3. (Presently amended) The method of claim 1 wherein ~~(the conditions resulting from greater than desirable)~~ said excess levels of secretion result in conditions which are selected from the group consisting of seborrheic dermatitis, rhinophyma, seborrheic blepharitis, and sebaceous cysts~~[, excess cerumen, unwanted milk production, and bacterial infections of these glands resulting in hidradenitis, fununcles, carbuncles, styes and chalazions].~~

4. (Originally filed) The method of claim 1 wherein the method of administration is topical.

5. (Presently amended) The method of claim 1 wherein the method of administration is by subdermal or intradermal injection.

6. (Originally filed) The method of claim 5 wherein injection is subdermal.

7. Cancelled.

8. (Originally filed) The method of claim 5 wherein injection is intradermal.

9. Cancelled

10. (Originally filed) The method of claim 6 comprising the subdermal injection of botulinum toxin A at multiple sites in the skin, wherein the sites of adjacent injections are separated by about 0.5 to 10 cm.

11. (Originally filed) The method of claim 10 wherein the sites of adjacent injections are separated by about 1.5 to about 3 cm.

12. – 13 . Cancelled

14. (Originally filed) The method of claim 8 comprising the intradermal injection of botulinum toxin A at multiple sites in the skin, wherein the sites of adjacent injections are separated by about 0.5 to 10 cm.

15. (Originally filed) The method of claim 14 wherein the sites of adjacent injections are separated by about 1.5 to about 3 cm.

16. (Presently amended) The method of claim ~~[9]~~ 6 comprising the ~~[intramuscular]~~ subdermal injection of botulinum toxin ~~[A]~~ at multiple sites in the skin, wherein the ~~[sites of adjacent injections are separated by about 0.5 to 10 cm]~~ amount injected is between 1 and 100U of botulinum toxin.

17. (Presently amended) The method of claim 16 wherein the ~~[sites of adjacent injections are separated by about 1.5 to about 3 cm]~~ amount injected is between 1 and 10U of botulinum toxin.

18. (Originally filed) The method of claim 6 wherein the amount injected is between 1 and 10 U of botulinum toxin A.

19. (Originally filed) The method of claim 18 wherein the amount injected is between 2 and 3 U of botulinum toxin A.

20. (Presently amended) The method of claim ~~7~~ 8 wherein the amount injected is between 1 and ~~[40]~~ 100U of botulinum toxin [A].

21. (Presently amended) The method of claim [29] 24 wherein the amount injected is between 2 and 3 U of botulinum toxin [A].

22. (Originally filed) The method of claim 8 wherein the amount injected is between 1 and 10 U of botulinum toxin A.

23. (Originally filed) The method of claim 22 wherein the amount injected is between 2 and 3 U of botulinum toxin A.

24. (Presently amended) The method of claim [9] 20 wherein the amount injected is between 1 and 10 U of botulinum toxin [A].

25. (Presently amended) The method of claim [24] 17 wherein the amount injected is between 2 and 3 U of botulinum toxin [A].

26. (Originally filed) The method of Claim 1, wherein said method is repeated periodically to inhibit the recurrence of undesirable levels of secretion.

27. (Originally filed) The method of Claim 26, wherein said method is repeated at intervals from about 3 months to about 6 months to inhibit said recurrence.

28. (Originally filed) The method of Claim 27, wherein said method is repeated at intervals of about 4 months to inhibit said recurrence.

29. (Originally filed) The method of Claim 1, wherein the botulinum toxin comprises botulinum toxin B.

30. (Originally filed) The method of Claim 1, wherein the botulinum toxin comprises botulinum toxin C.

31. (Originally filed) The method of Claim 1, wherein the botulinum toxin comprises botulinum toxin D.

32. (Originally filed) The method of Claim 1, wherein the botulinum toxin comprises botulinum toxin E.

33. (Originally filed) The method of Claim 1, wherein the botulinum toxin comprises botulinum toxin F.

34. (Originally filed) The method of Claim 1, wherein the botulinum toxin comprises botulinum toxin G.

35.-55. (Cancelled)

56. (Presently amended) . A method of smoothing fine wrinkles in the skin and decreasing the skin pore size of a ~~(-subject)~~ patient in need of same which comprises topically administering to said patient a pharmacologically effective amount of botulinum toxin whereby said fine wrinkles are smoothed.

57. (New) . A method of smoothing fine wrinkles in the skin and decreasing the skin pore size of a patient in need of same which comprises intradermally injecting said patient with a pharmacologically effective amount of botulinum toxin whereby said fine wrinkles are smoothed.